We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 27 million - 11% of adults - in the U.S., and has no approved pharmaceutical treaments.
Jan 29, 2020 Lyra Therapeutics Completes $30 Million Series C Financing
Jan 06, 2020 Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis
